Voyager Therapeutics (NASDAQ:VYGR) released its earnings results on Wednesday. The company reported ($0.41) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.83) by $0.42, Fidelity Earnings reports. Voyager Therapeutics had a negative net margin of 106.23% and a negative return on equity of 71.08%. The firm had revenue of $20.43 million during the quarter, compared to analysts’ expectations of $3.94 million.
Shares of NASDAQ VYGR traded up $0.38 during trading on Friday, hitting $14.86. 263,700 shares of the company traded hands, compared to its average volume of 451,389. The firm has a market capitalization of $548.84 million, a P/E ratio of -5.40 and a beta of 2.58. The company has a 50-day moving average price of $15.86 and a 200-day moving average price of $20.84. Voyager Therapeutics has a 1 year low of $7.76 and a 1 year high of $28.79.
VYGR has been the subject of several research reports. Cowen reissued a “buy” rating on shares of Voyager Therapeutics in a research note on Wednesday. HC Wainwright reissued a “buy” rating and set a $26.00 price objective on shares of Voyager Therapeutics in a research note on Monday, August 12th. Nomura reissued a “buy” rating and set a $37.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, August 13th. Wedbush reissued an “outperform” rating on shares of Voyager Therapeutics in a research note on Wednesday. Finally, Zacks Investment Research raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research note on Saturday, October 12th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $27.71.
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Further Reading: What are Bollinger Bands?
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.